Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Pharmacogenomics of Rare and Monogenic Disorders

The Role of Pharmacogenomics in Rare Diseases

[Rare diseases: unraveling the biological bases to find future therapies]

Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations

Next-Generation Therapeutics for Rare Genetic Disorders

Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Gene Therapy for Monogenic Disorders: Challenges, Strategies, and Perspectives

From target discovery to clinical drug development with human genetics

Progress and problem in the clinical application of pharmacogenomics

MicroRNAs and Long Non-coding RNAs in Genetic Diseases

Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Rare diseases, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis: Insights from landscape analysis of current research

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Rare diseases: Insights from landscape analysis of current research, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis

Genetic Treatment Approaches in Rare Pediatric Diseases

Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders

Shared etiology of Mendelian and complex disease supports drug discovery

Rare and low-frequency variants in human common diseases and other complex traits

Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine